The company was founded in 2010 by a number of multidisciplinary scientists and overseas experts in medicine, physics, biochemistry and other fields.

ANPAC is an early and leading advocate of the theory and methods of multifaceted, multiparameter cancer screening and multifaceted cancer detection. As early as around 2010, a number of ANPAC patent applications included multiple cancer detection rights claims, and in 2014, 16 cancer detection technologies were announced. At the 2015 American Society of Clinical Oncology (ASCO) Annual meeting, Ampacodo presented a paper on multi-cancer detection and Multifaceted multi-parameter. For more than ten years, ANPAC has adhered to the road of independent innovation, excelled in research and development, in-depth technology, and combined biochips, biophysics and biomedical methods across fields to overcome the technical problems of cancer early screening. Through cross-border innovation, biophysical technology combined with related biological MEMS chips is applied to disease detection, and breakthroughs are made in multi-cancer detection and multi-layer multi-parameter. Cancer Differentiation Analysis Technology (CDA technology) for cancer screening and detection has been developed.